GB9411045D0 - Compounds and use - Google Patents

Compounds and use

Info

Publication number
GB9411045D0
GB9411045D0 GB9411045A GB9411045A GB9411045D0 GB 9411045 D0 GB9411045 D0 GB 9411045D0 GB 9411045 A GB9411045 A GB 9411045A GB 9411045 A GB9411045 A GB 9411045A GB 9411045 D0 GB9411045 D0 GB 9411045D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB9411045A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to GB9411045A priority Critical patent/GB9411045D0/en
Publication of GB9411045D0 publication Critical patent/GB9411045D0/en
Priority to JP8500290A priority patent/JPH10500698A/en
Priority to EP95921759A priority patent/EP0763022A1/en
Priority to PCT/EP1995/002003 priority patent/WO1995033723A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
GB9411045A 1994-06-02 1994-06-02 Compounds and use Pending GB9411045D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GB9411045A GB9411045D0 (en) 1994-06-02 1994-06-02 Compounds and use
JP8500290A JPH10500698A (en) 1994-06-02 1995-05-24 Phenoxyalkyl-substituted piperidines, pyrrolidines, morpholines and thiomorpholines as calcium channel antagonists
EP95921759A EP0763022A1 (en) 1994-06-02 1995-05-24 Phenoxyalkyl substituted piperidines, pyrrolidines, morpholines and thiomorpholines as calcium channel antagonists
PCT/EP1995/002003 WO1995033723A1 (en) 1994-06-02 1995-05-24 Phenoxyalkyl substituted piperidines, pyrrolidines, morpholines and thiomorpholines as calcium channel antagonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9411045A GB9411045D0 (en) 1994-06-02 1994-06-02 Compounds and use

Publications (1)

Publication Number Publication Date
GB9411045D0 true GB9411045D0 (en) 1994-07-20

Family

ID=10756077

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9411045A Pending GB9411045D0 (en) 1994-06-02 1994-06-02 Compounds and use

Country Status (4)

Country Link
EP (1) EP0763022A1 (en)
JP (1) JPH10500698A (en)
GB (1) GB9411045D0 (en)
WO (1) WO1995033723A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU713236B2 (en) * 1996-02-15 1999-11-25 Sankyo Company Limited Diarly alkane derivatives containing an alicyclic group, their preparation and their theraputic and prophylactic uses
US6207662B1 (en) 1996-08-23 2001-03-27 Neurosearch A/S Disubstituted morpholine, oxazepine or thiazepine derivatives, their preparation and their use as dopamine D4 receptor antagonists
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6251919B1 (en) 1998-02-27 2001-06-26 Warner-Lambert Heterocyclic substituted aniline calcium channel blockers
US6166052A (en) 1998-03-11 2000-12-26 Warner-Lambert Company Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
WO2000021550A2 (en) * 1998-10-13 2000-04-20 President And Fellows Of Harvard College Methods and compositions for treating neurodegenerative diseases
AU2001290873B2 (en) 2000-09-11 2006-07-27 Sepracor Inc. Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission)
US7294637B2 (en) 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
KR20030037081A (en) * 2001-11-02 2003-05-12 한국과학기술연구원 Method for the suppression of visceral pain by regulating T-type calcium channel
EP1707203A1 (en) * 2005-04-01 2006-10-04 Bioprojet Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
EA017618B1 (en) * 2005-09-21 2013-01-30 Декод Дженетикс Ехф Biaryl substituted heterocycle inhibitors of lta4h for treating inflammation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9100513A (en) * 1990-08-06 1992-04-01 Smith Kline French Lab COMPOUNDS
MX9100517A (en) * 1990-08-06 1992-04-01 Smith Kline French Lab COMPOUNDS
GB9113031D0 (en) * 1991-06-17 1991-08-07 Smithkline Beecham Plc Compounds
JPH07503461A (en) * 1992-01-28 1995-04-13 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Compounds as calcium channel antagonists
GB9226111D0 (en) * 1992-12-15 1993-02-10 Smithkline Beecham Plc Madicaments

Also Published As

Publication number Publication date
WO1995033723A1 (en) 1995-12-14
JPH10500698A (en) 1998-01-20
EP0763022A1 (en) 1997-03-19

Similar Documents

Publication Publication Date Title
GB2298422B (en) Compounds and their use
IL116325A0 (en) Substituted 1h-imidazoles their preparation and use
EP0788489A4 (en) Heterocyclic compounds and their use
GB9702354D0 (en) Compounds and their use
GB9411045D0 (en) Compounds and use
HU9700071D0 (en) Use of muramilpeptides
EP0744125A3 (en) Iodo-complex and its use
IL116014A0 (en) Iminooxymethyleneanilides their preparation and their use
EP0799225A4 (en) Compounds and methods
GB9415901D0 (en) Novel compounds and treatment
GB9525048D0 (en) Composition compound and use
GB9415900D0 (en) Novel compounds and treatment
ZA959512B (en) Aryloxycycloalkenyl and aryloxyiminocycloalkenylhy-droxyureas
GB9413076D0 (en) Composition and use
GB9503091D0 (en) Compound and use
GB9411634D0 (en) Use and compounds
GB9417562D0 (en) Compounds and their use
GB9414881D0 (en) Compounds and their use
GB9525024D0 (en) Composition compound and use
GB9426435D0 (en) Compound and its use
GB9308091D0 (en) Compounds and use
GB9311223D0 (en) Compounds and use
GB9420243D0 (en) Complex and its use
GB9521111D0 (en) Composition compound and use
GB9406479D0 (en) Novel use